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Previous studies reported an association with multiple sclerosis (MS) of distinct HLA-class I markers, namely HLA-A*02,
HLA-Cw*05 and MOG-142L. In this work, we tested the association with MS of A*02 and Cw*05 in 1273 Italian MS patients
and 1075 matched controls, which were previously analyzed for MOG-142, and explored the relationship among these three
markers in modulating MS risk. HLA-A*02 conferred a statistically robust MS protection (odds ratio, OR¼0.61; 95% confidence
intervals, CI¼0.51–0.72, Po10
 9), which was independent of DRB1*15 and of any other DRB1* allele and remained similar
after accounting for the other two analyzed class I markers. Conversely, the protective effect we previously observed for MOG-
142L was secondary to its linkage disequilibrium with A*02. Cw*05 was not associated considering the whole sample, but its
presence significantly enhanced the protection in the HLA-A*02-positive group, independently of DRB1: the OR conferred by
A*02 in Cw*05-positive individuals (0.22, 95% CI¼0.13–0.38) was significantly lower than in Cw*05-negative individuals (0.69,
95% CI¼0.58–0.83) with a significant (P¼4.94 10
 5) multiplicative interaction between the two markers. In the absence of
A*02, Cw*05 behaved as a risk factor, particularly in combination with DRB1*03 (OR¼3.89, P¼0.0006), indicating that Cw*05
might be a marker of protective or risk haplotypes, respectively.
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Introduction
Multiple sclerosis (MS) is an autoimmune disease of the
central nervous system characterized by disseminated
and focal damage of myelin and axons, resulting in a
disabling condition.
1 The pathogenesis of MS is not
understood yet, but several studies suggest an interac-
tion of environmental and genetic factors.
2 The genetic
factor showing the strongest association with MS is
localized in the human Major Histocompatibility com-
plex (HLA) region on chromosome 6p21.3. The risk
haplotype that has been identified for the Caucasian
populations is HLA DRB1*1501-DQB1*0602 (also known
as DR15 haplotype) in the HLA-class II region. In the
Italian
3 as well as in other European populations,
4–6
DR15 confers an odds ratio (OR) of about 3.
In recent years, several studies have searched for the
presence of MS susceptibility factors in the HLA region
with an effect independent of HLA-DRB1. No evidence
of an HLA-A or -B association was found by Chao et al.
7
in 294 Canadian families. Moreover, none of the 1068
single-nucleotide-polymorphisms (SNPs) from a high-
density panel spanning the entire HLA genomic region
showed additional association in 1185 Canadian and
Finnish families after conditioning for HLA-DRB1.
8
Conversely, other studies have detected the effect at
Received 13 April 2009; revised 22 September 2009; accepted 23
September 2009; published online 12 November 2009
Correspondence: Dr S D’Alfonso, Department of Medical Sciences
and Interdisciplinary Research Center of Autoimmune Disease
(IRCAD), University of Eastern Piedmont, Via Solaroli 17, Novara
28100, Italy.
E-mail: dalfonso@med.unipmn.it
Genes and Immunity (2010) 11, 173–180
& 2010 Macmillan Publishers Limited All rights reserved 1466-4879/10 $32.00
www.nature.com/geneleast of one class I genetic factor independently of HLA-
DRB1. Brynedal et al.
9 confirmed in a Nordic cohort of
1084 MS patients and 1347 controls the results of a
previous study performed in a smaller Swedish panel,
10
showing that HLA-A*02 is negatively associated with
MS (OR¼0.63, P¼7 10
 12). Yeo et al.
11 analyzed over
1600 UK MS patients and 3600 controls and found that
HLA-Cw*05 exerts an MS-protective effect (OR¼0.49,
95% confidence intervals, CI¼0.34–0.69, P¼3.3 10
 5)
after excluding all individuals carrying DRB1 alleles
associated with MS. In a panel of 1124 Italian MS patients
and 1136 controls, we found a significant association
with the missense variant V142L (rs2857766) in the gene
encoding the Myelin Oligodendrocyte Glycoprotein
(MOG) mapping in the HLA-class I region, telomeric to
HLA-A (0.3Mb) and HLA-C (1.6Mb).
12 The 142L allele
(MOG-142L) conferred an OR¼0.70 (95% C.I¼0.60–0.82)
that remained similar after accounting for HLA-DRB1*15
carrier status.
12 Burfoot et al.
13 showed similar data in a
small Tasmanian population. Moreover, they reported a
negative association with HLA-A*02, but they did not
analyze if this variation was primarily associated or was
dependent on MOG-142L.
13
The relationship among the three reported HLA-class I
markers, A*02, Cw*05, MOG-142L and their association
with MS has not been examined so far.
In this work, we tested the association of A*02 and
Cw*05 in a large cohort of Italian MS patients and
controls, most of whom had been previously typed for
MOG-142 polymorphism, and we explored the relation-
ship among MOG-142L, HLA-A*02 and HLA-Cw*05 in
modulating MS risk.
Results
Association with MS of MOG-142L, HLA-A*02 and
HLA-Cw*05 in the Italian population
The MS association of MOG-142L, HLA-A*02 and HLA-
Cw*05 was tested in a case–control study (Table 1). The
frequency of MOG-142L and HLA-A*02-positive indivi-
duals was significantly lower in cases than in controls,
confirming the previously reported protective effect,
9,10,12,13
whereas the association with Cw*05 was not significant.
The comparison of genotype frequencies suggested
a dominant-protective effect of MOG-142L and of HLA-
A*02, as their frequency was significantly decreased both
among homozygous (OR¼0.55, 95% CI¼0.34–0.89 for
142L and OR¼0.55, 95% CI¼0.37–0.82 for A*02)a n d
heterozygous (OR¼0.75, 95% CI¼0.62–0.90 for 142L and
OR¼0.68, 95% CI¼0.57–0.81 for A*02)M Sp a t i e n t s .T h e
results did not change after adjustment for sex and were
not different among male and female cases in a stratified
analysis (data not shown). The results were not signifi-
cantly different in relapsing remitting and primary
progressive patients (data not shown).
To eliminate the possible confounding effect of linkage
disequilibrium (LD) with HLA-DRB1*15, we performed
the same analysis in DRB1*15-negative individuals.
The OR values for the three tested markers remained
substantially the same (Table 1).
The relative effect of the three tested HLA-class I
markers on MS risk was evaluated by logistic regression
analysis (Table 2). DRB1*15 was also included in the
model. All individuals were categorized according to the
presence or absence of each of the four considered
alleles. The OR conferred by A*02 remained similar after
accounting for each of the other markers included in the
model and for all the markers together, showing that the
protective effect was independent of any other analyzed
HLA marker. Conversely, the protective effect of MOG-
142L was abolished by adjustment for A*02. The lack of a
significant association with Cw*05 and the significant
risk effect of DRB1*15 were similar with and without the
adjustment for the remaining markers. This analysis
clearly showed that the association with MOG-142L was
not independent of HLA-A*02. This was also indicated by
an analysis stratified for HLA-A*02: MOG-142L was not
significantly associated either in the A*02 positive
(OR¼0.96 95% CI¼0.74–1.23, P¼0.76) or in the A*02
negative (OR¼0.80, 95% CI¼0.60–1.07, P¼0.13). These
results were explained by the strong LD (D0 ¼0.59;
r
2¼0.5) between the two alleles both in the control and in
the MS patient population (Table 3).
Considerable LD was also detected between A*02 and
Cw*05 in the control population (Table 3). Notably, it was
completely absent in the MS patients. This difference was
explained by the significantly decreased frequency of the
Table 1 Frequency of MOG-142L, HLA-A*02 and HLA-Cw*05-positive individuals among MS patients and controls
Marker Sample Frequencies P-value OR (95% CI)
Cases Controls
Total N¼1273 N¼1075
MOG-142L 0.285 0.364 4.93 10
 5 0.70 (0.59–0.83)
HLA-A*02 0.331 0.448 5.28 10
 9 0.61 (0.51–0.72)
HLA-Cw*05 0.101 0.112 NS 0.85 (0.65–1.10)
DR15 negative N¼883 N¼935
MOG-142L 0.293 0.377 1.42 10
 4 0.68 (0.56–0.84)
HLA-A*02 0.334 0.464 1.44 10
 8 0.58 (0.48–0.70)
HLA-Cw*05 0.108 0.119 NS 0.89 (0.66–1.21)
Abbreviations: CI, confidence intervals; MS, multiple sclerosis; OR, odds ratio; NS, not significant.
Genotype frequencies (+/+, +/ ,  / ) in the total MS patient sample vs total controls were 0.02, 0.26, 0.72 vs 0.04, 0.32, 0.64 for MOG-142L
and 0.04, 0.29, 0.67 vs 0.07, 0.38, 0.55 for HLA-A*02. These frequencies did not deviate from Hardy Weinberg equilibrium either in MS patients
or controls.
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Genes and ImmunityA*02þ, Cw*05þ phenotypic combination in the MS
patient as opposed to the control population (Table 4).
When analyzing in more detail the effect of the different
phenotypic combinations of the A*02 and Cw*05 alleles
on MS risk (Table 4), it appeared that the A*02þ,
Cw*05þ combination conferred an OR (0.38) signifi-
cantly lower than that (OR¼0.73) consequent to the
presence of A*02 in the absence of Cw*05. Conversely, in
the absence of HLA-A*02, Cw*05 showed a significant
positive association with MS (OR¼1.85). The same
results were seen when considering only DRB1*15-
negative individuals (Table 4).
Stratification for the HLA-Cw*05 revealed a sub-
stantial difference in risk conferred by the A*02 among
Table 2 Logistic regression analysis of MOG-142L, HLA-A*02, HLA-Cw* 05 and DRB1*15 alleles
Markers OR (95% CI) adjusted values for:
MOG-142L HLA-A*02 HLA-Cw*05 DRB1*15 All markers in the model
MOG-142L 0.70 (0.59–0.83) 0.87 (0.71–1.06)
P¼0.1761
0.70 (0.59–0.83)
P¼6.2 10
 5
0.73 (0.61–0.87)
P¼0.0004
0.90 (0.73–1.10)
HLA-A*02 0.65 (0.53–0.79)
P¼1.0 10
 5
0.61 (0.51–0.72) 0.61 (0.52–0.72)
P¼8.2 10
 9
0.63 (0.53–0.75)
P¼1.0 10
 7
0.66 (0.54–0.81)
HLA-Cw*05 0.87 (0.67–1.13)
P¼0.2970
0.90 (0.69–1.17)
P¼0.4167
0.85 (0.65–1.10) 0.88 (0.67–1.14)
P¼0.3348
0.92 (0.71–1.21)
DRB1*15 2.90 (2.34–3.59)
P¼2.8 10
 24
2.89 (2.33–3.58)
P¼6.3 10
 24
2.94 (2.37–3.64)
P¼4.6 10
 25
2.95 (2.38–3.65) 2.87 (2.32–3.56)
Abbreviations: CI, confidence intervals; OR, odds ratio.
Each marker in row is adjusted for markers in columns. In the last column the model includes all the markers.
The bolded diagonal values contain the crude values for each marker.
P-values are obtained from likelihood ratio test comparing the likelihood of the two-gene additive vs the single marker model considering as
single marker the marker used for adjustment.
Table 3 Linkage disequilibria among the three considered HLA-class I markers and DRB*15 in the control and in the MS patient population
Controls MS patients
MOG-142L A*02 Cw*05 DRB1*15 MOG-142L A*02 Cw*05 DRB1*15
MOG-142L   
A*02 0.587*** (0.469)   0.588*** (0.510)  
Cw*05 0.194* (0.091) 0.403*** (0.160)   0.002 (0.001)  0.003 (0.015)  
DRB1*15  0.011** (0.074)  0.014** (0.082)  0.001 (0.012)    0.006 (0.028)  0.003 (0.011)  0.003 (0.031)  
Abbreviation: MS, multiple sclerosis.
Numbers represent D0 (Lewontin’s delta) and r
2 (in brackets) values.
*Po0.05, **Po0.005 and ***Po0.000001.
Table 4 Phenotypic combinations of HLA-A*02 and HLA-Cw*05 in MS patients and controls
A*02 Cw*05 Sample Frequency P-value OR (95% CI)
Cases Controls
Total N¼1273 N¼1075
   0.599 0.513 2.4 10
 5 1.42 (1.21–1.68)
+ + 0.031 0.078 4.1 10
 7 0.38 (0.26–0.56)
+   0.299 0.370 2.8 10
 4 0.73 (0.61–0.86)
  + 0.070 0.039 0.001 1.85 (1.27–2.69)
DR15 negative N¼883 N¼935
   0.589 0.498 1.1 10
 4 1.44 (1.20–1.73)
+ + 0.031 0.081 1.8 10
 6 0.36 (0.23–0.56)
+   0.303 0.383 3.6 10
 4 0.70 (0.58–0.85)
  + 0.077 0.038 2.4 10
 4 2.15 (1.41–3.26)
Abbreviations: CI, confidence intervals; MS, multiple sclerosis; OR, odds ratio.
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Genes and ImmunityCw*05-positive individuals (OR¼0.22, 95% CI¼0.13–
0.38) and Cw*05-negative individuals (OR¼0.69, 95%
CI¼0.58–0.83). When stratifying for A*02, Cw*05 be-
haved as a protective factor among A*02-positive
individuals (OR¼0.50, 95% CI¼0.33–0.74) and as a risk
factor among A*02-negative individuals (OR¼1.53, 95%
CI¼1.04–2.24). The likelihood ratio test used to compare
the full model (including the two markers and the
interaction term) to the additive model (including
only the two markers) was statistically significant
(P¼4.9 10
 5). Thus, although HLA-Cw*05 and A*02
are not reciprocally confounders, as there was no
difference between crude and adjusted ORs (Table 2), the
stratification analysis showed a significant multiplicative
interaction between the two markers.
From the analysis in the case–control population, it
was not possible to distinguish whether the A*02þ,
Cw*05þ individuals carried the two alleles in cis or in
trans. We, therefore, analyzed the transmission of these
two alleles in 201 family trios. No Mendelian errors were
observed. Notably, out of 10 haplotypes that carried both
A*02 and Cw*05, none were transmitted to the MS
patients (T:NT¼0:10; P¼0.002). The only A*02þ,
Cw*05þ MS patient present in this panel inherited the
two alleles in trans. A*02-positive individuals of the
family trios were sequenced to define the A*02 alleles at a
higher resolution. In agreement with the literature
(http://www.allelefrequencies.net/), in these samples,
A*0201 was the most frequent A*02 allele (90%) followed
by A*0205 (8%) and A*0217 (2%). A*0201 was the most
represented A*02 allele both in the A*02þ, Cw*05þ and
in the A*02þ, Cw*05  haplotypes. The same proportion
of A*02 subtypes was seen among transmitted and non-
transmitted haplotypes (data not shown).
The joint effect of class I (A*02, Cw*05) and class II
(DRB1*15) markers on MS risk is reported in Figure 1.
All the combinations of these three alleles showed
a significantly increased risk relative to the A*02þ,
Cw*05þ, DRB1*15  phenotype, which is characterized
both by the presence of the class I markers conferring the
highest protection and by the absence of the class II allele
conferring the highest risk. The three combinations
carrying DRB1*15 in the absence of the highly protective
A*02þ, Cw*05þ phenotype (that is carrying only A*02
or only Cw*05 or none of them) showed a similar
eightfold increased risk. In the presence of both A*02 and
Cw*05, the DRB1*15 risk approximately halved to 4.57,
although this difference was not statistically significant
owing to the low frequency of this phenotype (N¼13 MS
patients and 8 controls). In the absence of DRB1*15,
a differently increased risk was observed according to
the presence of only A*02 (OR¼2.11) or only Cw*05
(OR¼5.47) or none of them (OR¼3.14).
Stratification for DRB1 alleles
To test whether the detected associations were conse-
quent on LD with DRB1 alleles different from DRB1*15,
we evaluated the relationship of HLA-A*02, Cw*05 and
their combinations with the DRB1 locus in a random
subset of 562 MS cases and 888 controls fully typed for
DRB1 at low resolution. In this subgroup, DRB1*15 was
positively MS associated with OR¼2.86 (95% CI¼2.14–
3.83; P¼8.4 10
 14). When considering DRB1*15-nega-
tive individuals, there was an additional significantly
positive association with DRB1*04 (OR¼1.88, 95%
CI¼1.34–2.63, P¼1.6 10
 4) and a negative association
with DRB1*07 of borderline significance (OR¼0.69, 95%
CI¼0.49–0.98, P¼0.036). At variance with other studies,
DRB1*03 was not associated (OR¼1.0, 95% CI¼0.72–
1.39). A modest global LD was detected between HLA-
A*02 and DRB1 (Global D0 ¼0.149, Cramer’s V¼0.176)
and between HLA-Cw*05 and DRB1 (Global D0 ¼0.280,
Cramer’s V¼0.194). The association with A*02 remained
significant after conditioning on the DRB1 locus by the
COCAPHASE program (unconditioned P¼1.9 10
 5;
conditioned P¼2.2 10
 4), thus showing that it is
independent of DRB1. Cw*05 was not significantly
associated (unconditioned P¼0.09; conditioned
P¼0.19). The OR conferred by HLA-A*02 did not
substantially change after conditioning for each DRB1
allele separately (data not shown). In addition, Cw*05
showed very similar results after conditioning for each
DRB1 allele with the notable exception of DRB1*03:a
protective effect with borderline significance was evi-
denced for HLA-Cw*05 when considering only DRB1*03-
negative individuals (OR¼0.58, 95% CI¼0.36–0.92;
P¼0.02). When the same procedure was applied to the
different A*02, Cw*05 combinations, there was no
substantial difference after conditioning for each DRB1
allele separately, again with the exception of DRB1*03
(Table 5). Interestingly, the A*02 negative, Cw*05 positive
combination was significantly increased among
DRB1*03-positive individuals (OR¼3.89), whereas it
was not significantly associated with MS among
DRB1*03-negative individuals (OR¼0.96). The A*02
positive, Cw*05 positive combination remained signifi-
cantly protective both in DRB1*03 positive (OR¼0.28)
and negative (OR¼0.39) individuals. Thus, the presence
of Cw*05 was significantly protective in combination
with A*02, independently of DRB1, whereas in the
absence of A*02, it behaved as a risk marker in
combination with DRB1*03 (Table 5).
Discussion
This work stems from previous studies undertaken by
our group and others, each reporting an MS association
with distinct HLA-class I markers, namely HLA-A*02,
9,13
HLA-Cw*05
11 and MOG-142L.
12 We here analyze the
relationship among these three markers for MS suscept-
ibility.
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Figure 1 ORs for the different combinations of A*02, Cw*05 and
DRB1*15 alleles. The combination carrying the HLA-class I alleles
conferring the highest protection (A*02þ, Cw*05þ) and without
the class II risk allele (DRB1*15 ) was used as a reference
(OR¼1) for the calculation of ORs. Figures in each bar correspond
to the 95% CI.
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Genes and ImmunityWe confirmed a strong protective effect of HLA-A*02,
which was independent of DRB1*15 as well as of any
other DRB1 allele. This association has now been
detected, with similar ORs, in three populations with a
different genetic background, respectively, from Italy
(this paper), Sweden
9 and Tasmania
13 based on a total of
over 2600 MS patients and 2700 controls. These data
concur to demonstrate a role in MS of this allele (or of a
variation in LD with it). Conversely, Chao et al.
7 failed to
observe a transmission distortion of the HLA-A*02 allele
in a large family sample from Canada and no SNPs in the
HLA-A region showed association with MS indepen-
dently of HLA-class II loci in Canadian and Finnish
families.
8 As both these studies were based on an
intrafamilial association method, an obvious explanation
of the discrepancy could be a stratification problem
related to the case–control approach used in the present
as well as the other two studies.
9,13 However, as a
significant HLA-A*02 association was seen in indepen-
dent studies and in three different populations, this
simple explanation seems unlikely and further studies
are needed to address this point.
The HLA-A*02 protection remained similar after
accounting for the other two analyzed class I markers.
Conversely, the protective effect of MOG-142L
was secondary to its high linkage disequilibrium with
HLA-A*02. This excluded a direct role of the missense
V142L variation in the MOG gene, a previously
suggested strong MS susceptibility candidate (reviewed
in D’Alfonso et al.
12).
In this study, Cw*05 was not associated with MS either
in the whole sample or in DRB1*15-negative individuals.
However, when stratifying the results separately for all
DRB1 alleles, Cw*05 conferred a significant protection for
MS in the subgroup of individuals negative for DRB1*03.
This is partially in line with the data reported by Yeo
et al.
11 who observed a protective effect of Cw*05 in the
whole sample as well as in individuals negative for
DRB1*03 and other MS-associated DRB1 alleles
(DRB1*15, DRB1*0103). Conversely, in DRB1*03-positive
individuals, and in the absence of A*02, Cw*05 was a risk
marker and conferred a risk similar to DRB1*15
(OR¼3.89, P¼0.0006). Moreover, Cw*05 significantly
enhanced the protection effect of HLA-A*02: the OR
conferred by A*02 among Cw*05-positive individuals
(OR¼0.22, 95% CI¼0.13–0.38) was about 1/3 smaller
than among Cw*05-negative individuals (OR¼0.69, 95%
CI¼0.58–0.83). Thus, although Cw*05 itself was not
significantly associated to MS, it behaved as a modifier of
the HLA-A*02-mediated protection. The protective effect
of the Cw*05-A*02 combination was independent of the
presence of DRB1*03 (Table 5).
These data suggest that the association of Cw*05
with MS varies according to its haplotypic context.
Cw*05 is a marker of three ancestral or conserved
extended HLA haplotypes,
14–16 one of which carries
DRB1*03 and is negative for A*02, namely 18.2 [A*30,
Cw*05, B*18, DRB1*03], and the other two carry A*02, but
not DRB1*03, namely 44.1 [A*0201, Cw*0501, B*4402,
DRB1*0401] and 18.3 [A*0201, Cw*0501, B*1801,
DRB1*1102].
The 18.2 HLA-extended haplotype is typical of the
Sardinian population and, to a lesser extent, of other
Mediterranean populations. Conversely, in the popula-
tions of northern European origin, this DR3 haplotype is
very rare and the majority of DRB1*03-positive indivi-
duals carry the 8.1 [A1, Cw*07, B*08, DRB1*03] extended
haplotype. The positive association of the A*02 ,
Cw*05þ, DRB1*03þ combination observed in this study
may reflect the effect of the 18.2 haplotype. It is tempting
to speculate that the strong positive association of MS
with DRB1*03 observed in Sardinia is related to the 18.2
haplotype and not only to DRB1*03 itself.
As stated above, the A*02-Cw*05 combination is
carried by two HLA ancestral haplotypes (44.1 and
18.3). However, as the individuals included in this study
were not typed for HLA-B and other HLA markers, from
our data it is not possible to conclude whether the
enhanced MS-protective effect of the A*02-Cw*05 combi-
nation is due to an haplotype effect (that is the presence
of a primarily associated protective factor carried by the
extended haplotype marked by A*02 and Cw*05)o rt oa
direct interactive role of the two markers.
The evidence in favor of an haplotype effect is as
follows: (i) Cw*05 was not associated with MS in the
absence of A*02. Actually, Cw*05 behaved as a protective
factor among A*02-positive individuals (OR¼0.50, 95%
CI 0.33–0.74) and as a risk factor among A*02-negative
individuals (OR¼1.53, 95% CI 1.04–2.24). (ii) In family
trios, out of 10 haplotypes that carried both A*02 and
Cw*05, none were transmitted to the MS patients
(T:NT¼0:10; P¼0.002). The only A*02þ, Cw*05þ MS
patient present in this panel inherited the two alleles in
trans. (iii) Each of the A*02, B*44 and Cw*05 alleles
Table 5 Distribution of the phenotypic combinations of HLA-A*02 and HLA-Cw*05 in MS patients and controls among DRB1*03-positive
and DRB1*03-negative individuals
A*02 Cw*05 Cases
N (%)
Controls
N (%)
OR 95% CI P-value
DRB1*03+
  + 20 (0.19) 10 (0.06) 3.89 1.74–8.66 0.0006
   57 (0.54) 82 (0.46) 1.34 0.83–2.18 NS
+ + 5 (0.05) 26 (0.15) 0.28 0.11–0.77 0.006
+   24 (0.23) 59 (0.33) 0.59 0.33–1.01 NS
DRB1*03 
  + 16 (0.04) 26 (0.04) 0.96 0.51–1.81 NS
   274 (0.60) 360 (0.51) 1.46 1.15–1.86 0.002
+ + 13 (0.03) 49 (0.07) 0.39 0.21–0.74 0.002
+   153 (0.34) 276 (0.39) 0.79 0.62–1.01 NS
Abbreviations: CI, confidence intervals; MS, multiple sclerosis; OR, odds ratio; NS, not significant.
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Genes and Immunity(characterizing the 44.1 ancestral haplotype) was sig-
nificantly decreased in the study of Yeo et al.
11 However,
the association with the A*02-B*44-Cw*05 haplotypic
combination was not investigated by the authors.
On the other hand, evidence reported in this study and
from work undertaken using an experimental animal
model
17 points to a direct role of A*02. In our study, A*02
was also significantly protective in the absence of Cw*05
(OR¼0.73, Po10
 4). Thus, an effect of A*02 alone cannot
be excluded. Moreover, Friese et al.
17 recently reported
that the MS-like disease developed by double transgenic
mice expressing both a human HLA-class I allele (A*03)
and a human myelin-specific autoreactive T-cell receptor
is completely prevented by further adding an HLA-
A*0201 transgene. Thus, A*02, which protects against MS
in human populations, also prevents an MS-like disease
in transgenic humanized mice. This protection resulted
from thymic deletion of autoreactive T cells, which
greatly reduced their number in the periphery.
17
Both HLA-A and -C genes are interesting candidates
for a direct role in MS pathogenesis, as their encoded
molecules present antigenic peptides and interact with
NK receptors.
18,19 However, several other genes in this
region might be primarily associated with MS. The
1.3Mb interval within HLA-A and -C genes contains 46
genes (24% of which encoding molecules involved in
immune functions) and about 4000 SNPs, according to
the recently reported sequence of eight HLA ancestral
haplotypes
20 and HapMap data (http://www.hapmap.
org/). A genome-wide association study
21 in about 1000
US MS patients and 1000 matched controls identified
several MS-associated SNPs in the HLA-class I region
after conditioning for HLA-DRB1*15. Among these, the
top signals were localized around members of the
tripartite motif (TRIM) gene family, mapping about
200kb centromeric to HLA-A. Although their function
is unknown, the presence of a RING domain suggests
DNA-binding activity.
21
In conclusion, this study provides additional suppor-
tive evidence indicating that the HLA-class I region does
indeed exert an additional influence on the risk of MS,
analogous to that reported for other autoimmune
diseases.
22–24 Moreover, it identifies haplospecific mar-
kers conferring a high MS protection. Notably, although
in general DRB1*15-negative individuals have an about
threefold lower MS risk relative to DRB1*15-positive
individuals, their risk was significantly decreased (about
eightfold) if they also carried A*02 and Cw*05 (Figure 1).
The highly protective A*02-Cw*05 combination is rare
(0.078 phenotypic frequency in our controls, 0.025
haplotype frequency in our family trios) and, therefore,
unless it tags a primary factor with higher frequency, it
confers a modest modification of the HLA attributable
MS risk in the population. In any case, the identification
of the mechanism mediating the protective effect might
throw new light on MS pathogenesis.
Materials and methods
Subjects
A total of 1273 Italian MS patients (female:male ratio 2:1)
diagnosed according to McDonald et al.,
25 were geno-
typed for the three HLA-class I markers considered in
this study and for DRB1*15. For 201 of these, a DNA
sample of the parents was also available (family trios).
The mean age of the MS patients at disease onset
was 31±10.16 years, the mean age at time of analysis
was 40±15.52 years and the mean disease duration was
12±9.31 years. Eighty-four percent of the patients were
affected by the relapsing remitting, 7% by the secondary
progressive and 9% by the primary progressive form of
the disease, defined according to Lublin and Reingold.
26
MS patients with Sardinian ancestors were excluded
to avoid the introduction of confounding sources of
heterogeneity. Enrolment of the MS patients followed
their informed consent. The study was approved by the
Ethical Committees of the collaborating clinical centers.
Controls included 1075 Italian individuals (medical
students, university and hospital staff, blood donors;
female:male ratio 1:1.1) matched for age and regional
origin with the MS patients and also typed for all
considered markers.
MS patients (82%) and controls (30%) in part overlap
with those included in a previous paper
12 and were
selected for inclusion on the basis of the availability of
DNA and of HLA genotypes.
MOG-V142L typing
The newly included samples were typed using a pre-de-
signed TaqMan SNP Genotyping Assay (probe code:
C__25474376_10). Reactions were performed according
to the manufacturer’s protocol using 25ng of DNA. The
PCR reaction was set up on a 7000 Applied Biosystems
instrument. Genotypes were detected using the 7000
System Software (Applied Biosystems, Foster City,
CA, USA).
A sub-sample of 60 individuals were typed both with
this method and with the method used in the previous
paper.
12 The results were consistent for all tested
samples.
HLA-A*02 typing
HLA-A exon 2 was amplified using a specific couple of
primers (Forward: 50-CGACGCCGCGAGCCAGARGAT-30,
Reverse: 50-GGCCCGTCCGTGGGGGATGA-30). The PCR
product (213bp) was digested using the restriction
enzyme Kpn2 I. This enzyme recognizes and cuts the
rs3173427-T sequence that is specific of HLA-A*02.B y
this approach, it was possible to distinguish HLA-A*02
homozygotes (displaying two fragments of 159 and
54bp) from heterozygotes (displaying three fragments
of 159, 54 and 213bp). The digestion was performed at
551C for 4h, and then the enzyme was inactivated at
801C for 20min.
HLA-A*02-positive individuals of family trios were
also analyzed by sequencing exon 2 and exon 3 to define
HLA-A*02 alleles at a higher resolution. Exon 2 and 3
were amplified together in the same fragment (Forward:
50-CGACGCCGCGAGCCAGARGAT-30, Reverse: 50-AA
CGGGAAGGAGACGCTGC-30). The reaction mix was
performed using 0.02Uml
–1 TaqAB, 0.2pmolml
–1 of every
primers, 1.75mM MgCl2 and glycerol to 7.4%. PCR was
made at 601C annealing temperature for 35 cycles. PCR
products were sequenced using nested primers: 50-
GGCCCGTCCGTGGGGGATGA-30 for exon 2 and 50-
TCAGTTTAGGCCAAAAATCC-30 for exon 3. Sequences
were analyzed with the automatic sequencer Applied
Biosystems (ABI) 3100.
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All the samples were typed for HLA-Cw*05 by an allele-
specific PCR after the conditions of the 12th International
Histocompatibility Workshop.
27 In detail, specific pri-
mers pairs were used to amplify in the same tube HLA-
Cw*05 (Forward: 50-CCGAGTGAACCTGCGGAAA-30,
Reverse: 50-CGCGCGCTGCAGCGTCTT-30) and a 796bp
internal control fragment (Forward: 50-TGCCAAGTGGA
GCACCCAA-30, Reverse: 50-GCATCTTGCTCTGTGCAG
AT-30). The reaction mix contained 0.02 Uml
–1 TaqAB (AB
Analitica), 1pmolml
–1 of HLA-Cw*05-specific primers,
0.33pmolml
–1 of internal control primers and 2mM of
MgCl2. By this approach, it was possible to specifically
identify all the samples positive for HLA-Cw*05, but not
to distinguish between Cw*05 homozygotes and hetero-
zygotes.
DRB1 locus analysis
For 562 MS cases and 888 controls, a complete low-
resolution DRB1 typing was already available. DRB1
alleles were typed by the DR low-resolution PCR-SSP
(Sequence Specific Primer amplification) kit (Dynal or
BAG, Formedic, Milan, Italy).
The remaining MS patients and controls were typed only
for DRB1*15 by an allele-specific PCR (Forward primer:
50-CCTGTGGCAGCCTAAGAGG-30, Reverse primer:
50-CCGCGCCTGCTCCAGGAT-30) with an internal con-
trol fragment (Forward: 50-TGTTCTGTATTTGTGTTG
TCTGATG-30, Reverse: 50-GTGCTCAGAGAGGCAAGG
TT-30). The reaction mix contained 0.02Uml
–1 TaqAB
(Applied Biosystems), 0.5pmolml
–1 DRB1*15-specific
primers, 0.25pmolml
–1 of internal control primers and
1.5mM of MgCl2. By this approach, it was possible to
specifically identify all the samples positive for DRB1*15,
but not to distinguish between DRB1*15 homozygotes
and heterozygotes.
Quality control of allele-specific HLA typing
The genotype methods used to type A*02, Cw*05 and
DRB1*15 alleles were validated by typing 51 HLA
homozygous typing cell lines from the reference panel
of the 12th International Histocompatibility Workshop
27
and 55 individuals previously typed with a com-
mercial kit.
Statistical analysis
Unconditional logistical regression was carried out to
determine the effect of the considered markers on MS
susceptibility. The association of each polymorphism
with the disease was measured by the OR and its 95% CI.
Reported P-values were not corrected for the number of
comparisons.
The potential confounding variables were assessed
individually by comparing the log-likelihood ratios
derived from a model with and without the variable.
This analysis was set up using multivariate models using
the four considered markers. All analyses were adjusted
for sex. The different models were compared by the
likelihood ratio test.
The interaction (modification) effect was assessed by
comparing ORs across levels of potential modifying
variables. Inclusion of appropriate interaction terms in
the logistic regression model was used to assess the
statistical significance of the interactions. For each
marker, the potential effect modification by sex variable
was also tested.
The main-effects test of the COCAPHASE program,
part of the UNPHASED suite,
28 was used for conditional
analysis on DRB1. This program provides association
tests conditioning on additional loci, which may already
be associated and in linkage disequilibrium with the test
loci. The EM algorithm is used to obtain maximium-
likelihood estimates of haplotypes.
LD were calculated from phenotypes according to
Mattiuz et al.
29 Estimates for Global D’ and Cramer’s V
(measures of LD between multiallelic loci) were calcu-
lated using the COCAPHASE program.
28
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